#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute respiratory distress syndrome Cholangiocarcinoma Lymphatic malformation Fms-like tyrosine kinase 3 positive Hormone-dependent prostate cancer Lymphoma Follicular lymphoma Infertility male B-cell lymphoma recurrent Haemolytic uraemic syndrome Human papilloma virus immunisation Myxoid liposarcoma Idiopathic pulmonary fibrosis Pemphigus Oesophageal adenocarcinoma stage III More trials…

    Learn about Rare Diseases

    Gastrointestinal stromal tumour Pulmonary fibrosis Anaplastic thyroid cancer – Diagnostics Osteosarcoma recurrent – Trials in Disease Hereditary ataxia – Trials in Disease Ehlers-Danlos syndrome – Diagnostics Factor VIII deficiency – Basic Information Pulmonary sarcoidosis – Diagnostics CADASIL – Diagnostics Pituitary-dependent Cushing’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Kan-101 Ecoo16 Pivekimab Sunirine Isis 696844 Oxybuprocaine Oric-114 Alclometasone Dipropionate Kd050 Fluticasone Furoate Azd4831 Pimecrolimus Tinzaparin Sodium SGT-003 IPN01195 Mrna-4157 Exl01 Afm24 Ubamatamab Apixaban For-6219 More therapies…

    Learn about Your Condition

    Thalassaemia beta Rectal cancer stage III Dilated cardiomyopathy Loeys-Dietz syndrome Anogenital dysplasia Arteriosclerosis Hypoxia Labour induction Spondylolisthesis Limb reduction defect Vaginal cancer Retinopathy proliferative Menopausal symptoms Anxiety disorder Endocrine ophthalmopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Thrombotic microangiopathy
    • Thrombotic thrombocytopenic purpura
    Investigated Drugs:
    • UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILLEBRAND FACTOR
    France Germany Italy Spain

  • Study of the effect of empagliflozin on protein levels in the urine for patients with type 2 diabetes and kidney disease.

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Chronic kidney disease
    Investigated Drugs:
    • Empagliflozin
    France

  • Study of dexamethasone injections for the management of chronic cervicobrachial neuralgia in adults who have not responded to standard medical treatments

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Dexamethasone
    France

  • Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Metyrapone
    France

  • A study to evaluate the effectiveness of nicotinamide in patients with Leber’s hereditary optic neuropathy who have experienced vision loss within the last 18 months

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hereditary optic atrophy
    Investigated Drugs:
    • Nicotinamide
    France

  • A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Austria Belgium Czechia Denmark Germany Hungary +3
Previous Page
1 … 736 737 738 739 740 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!